<?xml version="1.0" encoding="UTF-8"?>
<p>The Sanofi Pasteur chimeric yellow fever-dengue tetravalent dengue vaccine (CYD-TDV, Dengvaxia
 <sup>Â®</sup>) is used for the prevention of acute dengue caused by any of the four serotypes of dengue virus (DENV). This vaccine is licensed for use in individuals aged from 9 to 45 or 60 years old and living in endemic countries/areas with confirmed prior DENV infection. This population with prior DENV infection is at risk of secondary DENV infection, which is associated with increased risk of severe and hospitalized dengue.
</p>
